SIMPLE DISCOUNTS TO SUBSCRIPTION-BASED MODELS: WHAT IS THE FUTURE OF MULTI-INDICATION ONCOLOGY PRICING AND ACCESS?

被引：0
|
作者：
Doolub, N. [1 ]
Meszarosova, D. [1 ]
Poschen, C. [1 ]
机构：
[1] Precis Advisors, London, Lon, England
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN240
引用
收藏
页码：S465 / S465
页数：1
相关论文
共 16 条
  • [1] Indication-Based Pricing for Multi-Indication Drugs
    Adida, Elodie
    [J]. MANAGEMENT SCIENCE, 2023,
  • [2] HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?
    Karppinen, M. L.
    Ihalmo, P.
    Hjortsberg, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S82 - S83
  • [3] SYSTEMATIC LITERATURE REVIEW ON MULTI-INDICATION PRICING MODELS IN ONCOLOGICAL DRUGS
    Manganelli, A.
    Badia, X.
    Gonzalez, P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A467 - A467
  • [4] COMPARISON OF THE GERMAN MIXED PRICE MODEL AND INDICATION-PECIFIC PRICING FOR MULTI-INDICATION PRODUCTS IN ONCOLOGY
    Mossmann, W.
    Scherrer, F.
    [J]. VALUE IN HEALTH, 2018, 21 : S82 - S82
  • [5] Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications
    Auty, Samantha G.
    Shafer, Paul R.
    Griffith, Kevin N.
    [J]. JAMA HEALTH FORUM, 2021, 2 (08): : E212291
  • [6] UTILISATION OF SURVIVAL OUTCOMES DATA TO FORECAST ECONOMIC IMPACT OF PRICING AND MARKET ACCESS SCENARIOS IN A MULTI-INDICATION PATIENT FLOW MODELS
    Sogokon, P.
    Hunt, M.
    Kjeldgaard-Pedersen, J.
    Furneri, G.
    Chalmers, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A399 - A399
  • [7] Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs
    Jiang, Yawen
    Li, Meng
    Jiang, Shan
    Si, Lei
    Gu, Yuanyuan
    [J]. VALUE IN HEALTH, 2024, 27 (03) : 273 - 277
  • [8] Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
    Mills, Mackenzie
    Kanavos, Panos
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (04) : 553 - 565
  • [9] Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
    Mackenzie Mills
    Panos Kanavos
    [J]. PharmacoEconomics - Open, 2023, 7 : 553 - 565
  • [10] Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies
    Ha, So-Young
    Kang, Dong-Won
    Jung, Hye-In
    Lee, Eui-Kyung
    Park, Mi-Hai
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (07)
12